Academic Journal
Eltrombopag in patients with chronic immune thrombocytopenia in Asia-Pacific, the Middle East, and Turkey: final analysis of CITE
| العنوان: | Eltrombopag in patients with chronic immune thrombocytopenia in Asia-Pacific, the Middle East, and Turkey: final analysis of CITE |
|---|---|
| المؤلفون: | Elghandour, Ashraf, Mattar, Mervat, Rahman, Masiur, Ingles, Sara, Wei, Xie, Yoon, Sung-Soo, TARKUN, PINAR, Yassin, Mohamed A., Yavaşǒglu, Irfan, Wong, Raymond Siu Ming, ÖZCAN, MEHMET, Goldbrunner, Michael, Angchaisuksiri, Pantep, Yang, Renchi, Frueh, Jennifer A., Jang, Jun Ho |
| سنة النشر: | 2023 |
| المجموعة: | Dokuz Eylül University: DSpace Repository |
| الوصف: | CITE was a prospective, noninterventional study in adult patients with chronic immune thrombocytopenia treated with eltrombopag under routine clinical care in Asia-Pacific, the Middle East, and Turkey. Data to assess eltrombopag usage, compliance, and outcomes were collected from May 2017 to December 2020. Platelet response was defined as platelet count ≥50 × 103/μL in the absence of rescue medications and splenectomy. Quality of life was evaluated using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) questionnaire. Noncompliance was defined as the number of missed doses and number of days where the patient did not follow food instructions. A total of 231 patients were enrolled; the median (range) duration of eltrombopag treatment was 484.5 (1-642) days. Compliance to prescribed eltrombopag dose since the previous routine visit was high at ≥96.0%. Baseline median platelet count was 19.0 × 103/μL, which increased to ≥50 × 103/μL at month 2 and mostly fluctuated between 70 × 103/μL and 100 × 103/μL thereafter. The median time to first platelet response was 1.05 (95% confidence interval: 0.92-1.28) months, and the median (interquartile range) maximum duration of platelet response was 193 (57-456) days. FACIT-F scores improved from a mean (standard deviation) 34.4 (12.1) at baseline to 38.5 (9.1) at month 18. Adverse events occurred in 50.9% of patients (n = 116), the most common being upper respiratory tract infection (8.3%) and headache (6.6%). These findings confirmed the effectiveness of eltrombopag treatment in routine practice and reassured that real-world compliance to eltrombopag-prescribed doses and dietary instructions in Asia-Pacific, the Middle East, and Turkey were in line with current recommendations. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| Relation: | 06f9d905-8eb6-4fce-80d7-ff6b06e48e88; https://avesis.deu.edu.tr/publication/details/06f9d905-8eb6-4fce-80d7-ff6b06e48e88/oai |
| DOI: | 10.1182/bloodadvances.2022008287 |
| الاتاحة: | https://doi.org/10.1182/bloodadvances.2022008287 https://avesis.deu.edu.tr/publication/details/06f9d905-8eb6-4fce-80d7-ff6b06e48e88/oai |
| Rights: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.8BF65532 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1182/bloodadvances.2022008287 |
|---|